share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  07/30 08:05
Moomoo AI 已提取核心訊息
On July 30, 2024, 180 Life Sciences Corp. announced positive topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. The study, conducted in collaboration with Prof. Avi Domb of the Hebrew University and Prof. Elyad Davidson of Hadassah Hospital, compared the pharmacokinetic profile of two solid CBD formulations against Epidiolex, an FDA-approved drug for epilepsy. Twelve volunteers participated in a crossover randomized trial, revealing that one of the solid forms was absorbed faster and reached higher maximal levels than Epidiolex, while both solid forms were well tolerated. The company believes that the solid formulation could advance the testing of CBD in other indications, such as pain and PTSD, due to its potential benefits and more desirable pill format. The full study results are pending and are expected to be submitted for scientific publication at a later date. 180 Life Sciences Corp. does not anticipate the trial's outcome to impact its financial results for the year ended December 31, 2024.
On July 30, 2024, 180 Life Sciences Corp. announced positive topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) with enhanced oral uptake. The study, conducted in collaboration with Prof. Avi Domb of the Hebrew University and Prof. Elyad Davidson of Hadassah Hospital, compared the pharmacokinetic profile of two solid CBD formulations against Epidiolex, an FDA-approved drug for epilepsy. Twelve volunteers participated in a crossover randomized trial, revealing that one of the solid forms was absorbed faster and reached higher maximal levels than Epidiolex, while both solid forms were well tolerated. The company believes that the solid formulation could advance the testing of CBD in other indications, such as pain and PTSD, due to its potential benefits and more desirable pill format. The full study results are pending and are expected to be submitted for scientific publication at a later date. 180 Life Sciences Corp. does not anticipate the trial's outcome to impact its financial results for the year ended December 31, 2024.
180生命科學公司於2024年7月30日宣佈，一項評估經增強口服吸收的新型固體類可卡因（CBD）製劑的臨床藥理學研究取得了積極的前期結果。該研究與希伯來大學的Avi Domb教授和Hadassah醫院的Elyad Davidson教授合作進行，比較了兩種CBD固體制劑與FDA批准的癲癇藥物Epidiolex的藥代動力學特徵。十二名志願者參加了隨機交叉試驗，結果表明固體形態之一的吸收速度更快，達到的最大水平比Epidiolex高，而兩種固體形態均耐受良好。該公司相信，該固體制劑可能推動CBD在其他適應症的測試，如疼痛和創傷後應激障礙（PTSD），由於其潛在的益處和更理想的藥丸形式。完整的研究結果尚待公佈，並預計將在以後的科學出版物上提交。180生命科學公司不預計該試驗結果會影響其截至2024年12月31日的財務業績。
180生命科學公司於2024年7月30日宣佈，一項評估經增強口服吸收的新型固體類可卡因（CBD）製劑的臨床藥理學研究取得了積極的前期結果。該研究與希伯來大學的Avi Domb教授和Hadassah醫院的Elyad Davidson教授合作進行，比較了兩種CBD固體制劑與FDA批准的癲癇藥物Epidiolex的藥代動力學特徵。十二名志願者參加了隨機交叉試驗，結果表明固體形態之一的吸收速度更快，達到的最大水平比Epidiolex高，而兩種固體形態均耐受良好。該公司相信，該固體制劑可能推動CBD在其他適應症的測試，如疼痛和創傷後應激障礙（PTSD），由於其潛在的益處和更理想的藥丸形式。完整的研究結果尚待公佈，並預計將在以後的科學出版物上提交。180生命科學公司不預計該試驗結果會影響其截至2024年12月31日的財務業績。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息